Premature Ejaculation Treatment Market to Record a CAGR of 9.06%, High Efficacy of Off-label Drugs to Boost Market Growth - Technavio
NEW YORK, Sept. 9, 2022 /PRNewswire/ -- The "Premature Ejaculation Treatment Market by Route of Administration (Oral and Topical), Drug Class (SSRIs, PDE5 inhibitors, Amide Anesthetics, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW)) - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. The potential growth difference for the premature ejaculation treatment market size between 2021 and 2026 is USD 1.26 bn. To get the exact CAGR and the Y-O-Y growth rate, Request a FREE PDF Sample Report
Key Market Dynamics:
Market Driver: The high efficacy of off-label drugs is driving the growth of the market. The use of off-label drugs of different drug classes, including SSRIs and PDE5 inhibitors, has increased owing to their effectiveness in the treatment of premature ejaculation. In addition, according to some clinical studies, combining PDE5 inhibitors with SSRIs leads to better results in the treatment of premature ejaculation than using SSRIs alone. Thus, the high efficacy of these drugs is increasing their demand among end-users, which is contributing to the growth of the global premature ejaculation treatment market.
Market Challenge: The availability of alternative treatment options is challenging the growth of the market. The rising number of premature ejaculation cases across the world has led to a growth in the number of alternative treatment methods for the disease. Some of the alternate treatment methods include homeopathy, psychotherapy, yoga, counseling, and herbal therapy. Some of these treatment options are believed to have little or no side effects when compared to mainstream premature ejaculation treatment drugs. Thus, the rising popularity of alternative premature ejaculation treatment options has hindered the growth of pharmacological therapies, which is posing a threat to market growth.
By route of administration, the oral segment will be the largest contributor to market growth during the forecast period. These drugs are available in different forms, such as capsules, tablets, and liquids. The growth of this segment is attributed to factors such as the popularity and high preference for oral medication as the first line of treatment for premature ejaculation.
By geography, North America will be the leading region with 39% of the market's growth during the forecast period. The US is the key country for the premature ejaculation treatment market in North America. The growth of this region is attributed to factors such as a significant increase in the number of premature ejaculation cases. However, market growth in this region will be slower than the growth of the market in other regions.
View our FREE PDF sample reportfor additional insights into the contribution of all the segments and regional opportunities in the report.
Some Companies Mentioned
A. Menarini Industrie Farmaceutiche Riunite Srl
Absorption Pharmaceuticals LLC
Alembic Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc.
ANI Pharmaceuticals Inc.
Aytu BioPharma Inc.
Bayer AG
Cipla Ltd.
Eli Lilly and Co.
Endurance RP Ltd.
GlaxoSmithKline Plc
Johnson and Johnson
Lupin Ltd.
NeuroHealing Pharmaceuticals Inc.
Novitium Pharma
Pfizer Inc.
Plethora Solutions Ltd.
Sandoz International GmbH
Solco Healthcare
Teva Pharmaceutical Industries Ltd.
Want your report customized? Speak to an analyst and personalize your report according to your needs
Exhibit 150: Validation techniques employed for market sizing
Exhibit 151: Information sources
12.5 List of abbreviations
Exhibit 152: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. between March 9, 2023 and February 29, 2024, both dates inclusive (the "Class Period"), of the important August 6, 2024 lead plaintiff...
The global feminine hygiene wash market size is estimated to grow by USD 124.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 5.17% during the forecast period. Advertising and promotion of...
The global marine loading arms market size is estimated to grow by USD 65.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 3.43% during the forecast period. Rise in demand for oil and gas...
The global payment gateways market size is estimated to grow by USD 11.23 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 13.42% during the forecast period. High adoption of contactless payment...
The global wellness real estate market size is estimated to grow by USD 1.26 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 32.14% during the forecast period. Rising demand for wellness real estate from...
Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the...